NCT03733587View on ClinicalTrials.gov

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

April 2, 2020

Study Completion Date

May 13, 2020

Conditions
Solid Tumor
Interventions
DRUG

GX-I7

GX-I7 25mg/ml/vial

DRUG

Cyclophosphamide

Cyclophosphamide 500mg/vial

Trial Locations (2)

Unknown

Seoul National University Bundang Hospital, Seongnam-si

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT03733587 - GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter